Chengdu Climb Pharmaceutical Technology Co.,Ltd.

86-28-87608726

  At present, our company research and declare 5 items (API + Preparation).Originally registered class 3.1, we have two.  Ulipristal acetate and tablets, Macitentan and tablets, both has received clinical trial approval.Originally registered class 6, we have 3. One of them has been approved for bioequivalence tests. In the process of drug research and development, we applied for patent protection for innovative technologies,Up to now, we have applied for 17 patents for inventions, 8 of which have been obtained patent certificates, and the others are in the review.

Patent Number

Invention Name

201410232233.4

A new method for synthesis of moxifloxacin hydrochloride

201410476437.2

Method for determination of residual acetic acid in Moxifloxacin Hydrochloride

201410563759.0

A new method for preparation of intermediates of Macitentan

201510319073.1

A detection method of high performance liquid parecoxib sodium isomer chromatography

201510002045.7

A synthetic method of parecoxib sodium impuritiesImpurity B

201510247288.7

Method for detecting intermediates of Macitentan and application

201510003035.5

A synthetic method of parecoxib sodium impuritiesImpurity I

201410300271.9

A new method for the preparation of Etoricoxib intermediate 1-(6-Methylpyridin-3-yl)-2-[4(methylsulfonyl)phenyl]ethanone